目的 探討復(fù)方羊角片聯(lián)合對乙酰氨基酚治療偏頭痛的臨床療效。方法 選取2016年7月—2017年7月在徐州民政醫(yī)院進行診治的偏頭痛患者74例，根據(jù)用藥的不同分為對照組（37例）和治療組（37例）。對照組口服復(fù)方對乙酰氨基酚片，1片/次，若持續(xù)疼痛則1次/4～6 h，24 h內(nèi)用藥<4片；治療組在對照組基礎(chǔ)上口服復(fù)方羊角片，5片/次，3次/d。兩組患者均治療4周。觀察兩組患者臨床療效，比較治療前后兩組患者臨床癥狀改善情況和血清細(xì)胞因子水平。結(jié)果 治療后，對照組臨床有效率為81.08%，顯著低于治療組的97.30%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組頭痛發(fā)作次數(shù)、持續(xù)時間和發(fā)作程度評分均明顯下降，同組比較差異具有統(tǒng)計學(xué)意義（P<0.05）；且治療組改善后臨床癥狀顯著優(yōu)于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組血清同型半胱氨酸（HCY）、溶血磷脂酸（LPA）、基質(zhì)金屬蛋白酶-9（MMP-9）水平顯著降低，5羥色胺（5-HT）和β內(nèi)啡肽（β-EP）水平顯著升高，同組比較差異具有統(tǒng)計學(xué)意義（P<0.05）；且治療組上述血清細(xì)胞因子水平明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 復(fù)方羊角片聯(lián)合復(fù)方對乙酰氨基酚治療偏頭痛可有效改善患者臨床癥狀，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical efficacy of Compound Yangjiao Tablets combined with compound paracetamol in treatment of migraine. Methods Patients (74 cases) with migraine in Xuzhou Civil Administration Hospital from July 2016 to July 2017 were divided into control (37 cases) and treatment (37 cases) based on different treatment. Patients in the control group were po administered with Compound Paracetamol Tablets, 1 tablet/time, once every 4-6 h for the persistent pain, and less than 4 tablets in 24 h. Patients in the treatment group were po administered with Compound Yangjiao Tablets on the basis of the control group, 5 tablets/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the improvement of clinical symptoms, the cytokine levels in two groups before and after treatment was compared. Results After treatment, the clinical efficacy in the control group was 81.08%, which was significantly lower than 97.30% in the treatment group and there were differences between two groups (P < 0.05). After treatment, the headache frequency, headache duration and degree of headache scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the clinical symptom after treatment in the treatment group was significantly better than that in the control group, with significant difference between two groups (P < 0.05). After treatment, the HCY, LPA, MMP-9 levels in two groups were significantly decreased, but 5-HT and β-EP levels were significantly increased, and there were differences in the same group (P < 0.05). And the cytokine levels in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Compound Yangjiao Tablets combined with paracetamol can obviously improve clinical symptoms in treatment of migraine, which has a certain clinical application value.